All In Biotech

Drug Trial Radar · NCT05180526

Assessment of Safety , Clinical Efficacy With QLETLI in Non-infectious Uveitis (UV)

A Multicenter, Prospective, Post-marketing Evaluation of QLETLI (Adalimumab Injection) Treatment Clinical Study on Efficacy and Safety of Non-infectious Uveitis (UV)

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Dec 27, 2021

Primary completion

Aug 5, 2025

Study completion Aug 5, 2025

Sponsor

Lead sponsor
Bio-Thera SolutionsIndustry
Sponsor type
Industry
First posted
Jan 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, prospective, post-marketing clinical study with a total of 60 uveitis (UV) subjects planned to be enrolled. Screening period (-2\~0 weeks) ,Treatment period (1-22 weeks), Follow-up period, At the same time, plasma concentration will be determined

Conditions

  • Uveitis

Interventions

  • QLETLIDrug

    80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of treatment failureTime frame: 6\12\24week

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China

  • The Second Xiangya Hospital of Central South University

    Changsha, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, China

  • The second hospital of Jilin University

    Jilin City, China

  • Tianjin Medical University Eye Hospital

    Tianjin, China

  • Renmin Hospital of Wuhan University

    Wuhan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.